ArticleStem cells translational medicine2026
Ckb-Cryab-Drp1 axis enhances BMSC osteogenic differentiation and mouse alveolar bone healing through mitochondrial fission modulation.
Article in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Repairing bone defects resulting from trauma, infection, or tumor resection remains a significant challenge in clinical practice. Particularly in the oral and maxillofacial region, achieving predictable bone regeneration is especially difficult due to the complex anatomical structure and the critical need for optimal aesthetic and functional outcomes. A deeper understanding of the molecular mechanisms governing osteogenic differentiation is therefore essential to develop effective strategies for bone repair. Although creatine kinase B (Ckb) is known for its role in energy metabolism, its function in bone regeneration remains poorly understood. In this investigation, we found that Ckb is specifically expressed in jaw mesenchymal cells. Functional assays demonstrated that Ckb promoted osteogenic differentiation of bone marrow mesenchymal stem cells in vitro. Consistently, Ckb overexpression promoted alveolar bone healing in a mouse tooth-extraction model, while Ckb knockdown impaired bone regeneration. We discovered that Ckb localized to mitochondria and enhanced mitochondrial fission by increasing dynamin-related protein 1 (Drp1) Ser616 phosphorylation. The pro-osteogenic impact of Ckb was reduced by pharmacologically inhibiting mitochondrial fission with Mdivi-1. This result was replicated by Drp1 knockdown, indicating that Drp1 is essential for Ckb-mediated osteogenesis. Transcriptome sequencing identified αB-crystallin (Cryab) as a key downstream effector of Ckb, and co-immunoprecipitation confirmed a physical interaction between Ckb and Cryab. Crucially, Cryab overexpression rescued the osteogenic and mitochondrial dysfunction caused by Ckb knockdown. Collectively, our research reveals a unique Ckb-Cryab-Drp1 axis that controls mitochondrial dynamics to coordinate osteogenesis, offering a molecular basis for guiding MSC-based bone regeneration techniques.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.